Roger Bedimo1, Lisa Rosenblatt2, Joel Myers2. 1. a Department of Medicine , VA North Texas Health Care System, University of Texas Southwestern Medical Center , Dallas , TX , USA. 2. b Bristol-Myers Squibb , Plainsboro , NJ , USA.
Abstract
BACKGROUND: Tenofovir disoproxil fumarate (TDF) is a component of many combinations of antiretroviral treatment (ART) regimens. Although potent and generally well tolerated, TDF may cause renal and bone toxicity. The magnitude of off-target side effects is proposed to be related to tenofovir plasma concentrations, which are affected by food and drug-drug interactions with concomitant antiretrovirals. OBJECTIVE: To perform a systematic literature review and qualitatively report on renal and bone safety outcomes associated with efavirenz (EFV), emtricitabine (FTC), and TDF (EFV+FTC+TDF) ART. METHODS: Embase and PubMed databases were searched for randomized clinical trials and observational cohort studies reporting on HIV treatment with EFV+FTC+TDF. Relevant articles were hand-searched for renal (Grade 3-4 serum creatinine/estimated glomerular filtration rate elevations, renal adverse events [AEs], discontinuation due to renal AEs, and urinary biomarkers) and bone outcomes (bone mineral density [BMD] reductions, bone turnover markers, and fracture), and results compiled qualitatively. RESULTS: Of 337 retrieved articles, 29 reporting renal and 11 reporting bone outcomes met the review criteria. EFV+FTC+TDF was associated with a low frequency of renal AEs and treatment discontinuations due to renal AEs. Renal AEs were more frequent when TDF was taken with protease inhibitor (PI)- or cobicistat-containing ART. EFV+FTC+TDF was associated with reduced BMD and increased bone turnover markers, but BMD reductions were less than with PI-containing ART. No treatment-related bone fractures were identified. CONCLUSIONS: EFV+FTC+TDF appeared to have a more favorable renal safety profile than TDF administered with a PI or cobicistat. BMD decreased with EFV+FTC+TDF, but no treatment-related fractures were identified.
BACKGROUND:Tenofovir disoproxil fumarate (TDF) is a component of many combinations of antiretroviral treatment (ART) regimens. Although potent and generally well tolerated, TDF may cause renal and bone toxicity. The magnitude of off-target side effects is proposed to be related to tenofovir plasma concentrations, which are affected by food and drug-drug interactions with concomitant antiretrovirals. OBJECTIVE: To perform a systematic literature review and qualitatively report on renal and bone safety outcomes associated with efavirenz (EFV), emtricitabine (FTC), and TDF (EFV+FTC+TDF) ART. METHODS: Embase and PubMed databases were searched for randomized clinical trials and observational cohort studies reporting on HIV treatment with EFV+FTC+TDF. Relevant articles were hand-searched for renal (Grade 3-4 serum creatinine/estimated glomerular filtration rate elevations, renal adverse events [AEs], discontinuation due to renal AEs, and urinary biomarkers) and bone outcomes (bone mineral density [BMD] reductions, bone turnover markers, and fracture), and results compiled qualitatively. RESULTS: Of 337 retrieved articles, 29 reporting renal and 11 reporting bone outcomes met the review criteria. EFV+FTC+TDF was associated with a low frequency of renal AEs and treatment discontinuations due to renal AEs. Renal AEs were more frequent when TDF was taken with protease inhibitor (PI)- or cobicistat-containing ART. EFV+FTC+TDF was associated with reduced BMD and increased bone turnover markers, but BMD reductions were less than with PI-containing ART. No treatment-related bone fractures were identified. CONCLUSIONS:EFV+FTC+TDF appeared to have a more favorable renal safety profile than TDF administered with a PI or cobicistat. BMD decreased with EFV+FTC+TDF, but no treatment-related fractures were identified.
Authors: Ian McGowan; Timothy Wilkin; Raphael J Landovitz; Chunyuan Wu; Ying Chen; Mark A Marzinke; Craig W Hendrix; Paul Richardson; Susan H Eshleman; Adriana Andrade; Wairimu Chege; Peter L Anderson; Marybeth McCauley; Jason Farley; Kenneth H Mayer; Peter Anton; Rhonda M Brand; Ross D Cranston; Roy Gulick Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Denise L Jacobson; Wendy Yu; Rohan Hazra; Sean Brummel; Mitchell E Geffner; Kunjal Patel; William Borkowsky; Jiajia Wang; Janet S Chen; Ayesha Mirza; Linda A DiMeglio Journal: Bone Date: 2020-06-30 Impact factor: 4.398
Authors: Mariska C Vlot; Marlous L Grijsen; Jan M Prins; Renate T de Jongh; Robert de Jonge; Martin den Heijer; Annemieke C Heijboer Journal: PLoS One Date: 2018-03-09 Impact factor: 3.240
Authors: Joanne LaFleur; Adam P Bress; Joel Myers; Lisa Rosenblatt; Jacob Crook; Kristin Knippenberg; Roger Bedimo; Pablo Tebas; Heather Nyman; Stephen Esker Journal: Infect Dis Ther Date: 2018-02-28
Authors: Willem Daniel Francois Venter; Andrew Kambugu; Matthew F Chersich; Stephen Becker; Andrew Hill; Natasha Arulappan; Michelle Moorhouse; Mohammed Majam; Godspower Akpomiemie; Simiso Sokhela; Selvamuthu Poongulali; Charles Feldman; Chris Duncombe; David H Brown Ripin; Alinda Vos; Nagalingeswaran Kumarasamy Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731